These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 28416280)

  • 1. Progress toward Gene Therapy for Duchenne Muscular Dystrophy.
    Chamberlain JR; Chamberlain JS
    Mol Ther; 2017 May; 25(5):1125-1131. PubMed ID: 28416280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy.
    Nance ME; Duan D
    Hum Gene Ther; 2015 Dec; 26(12):786-800. PubMed ID: 26414293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy.
    Zhang Y; Yue Y; Li L; Hakim CH; Zhang K; Thomas GD; Duan D
    Hum Mol Genet; 2013 Sep; 22(18):3720-9. PubMed ID: 23681067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice.
    Koo T; Malerba A; Athanasopoulos T; Trollet C; Boldrin L; Ferry A; Popplewell L; Foster H; Foster K; Dickson G
    Hum Gene Ther; 2011 Nov; 22(11):1379-88. PubMed ID: 21453126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models.
    Song Y; Morales L; Malik AS; Mead AF; Greer CD; Mitchell MA; Petrov MT; Su LT; Choi ME; Rosenblum ST; Lu X; VanBelzen DJ; Krishnankutty RK; Balzer FJ; Loro E; French R; Propert KJ; Zhou S; Kozyak BW; Nghiem PP; Khurana TS; Kornegay JN; Stedman HH
    Nat Med; 2019 Oct; 25(10):1505-1511. PubMed ID: 31591596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients.
    Duan D
    Hum Gene Ther; 2018 Jul; 29(7):733-736. PubMed ID: 29463117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.
    Ahmad A; Brinson M; Hodges BL; Chamberlain JS; Amalfitano A
    Hum Mol Genet; 2000 Oct; 9(17):2507-15. PubMed ID: 11030755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro assay for the efficacy assessment of AAV vectors expressing microdystrophin.
    Danilov KA; Vassilieva SG; Polikarpova AV; Starikova AV; Shmidt AA; Galkin II; Tsitrina AA; Egorova TV; Orlov SN; Kotelevtsev YV
    Exp Cell Res; 2020 Jul; 392(2):112033. PubMed ID: 32360435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression.
    Wang Z; Kuhr CS; Allen JM; Blankinship M; Gregorevic P; Chamberlain JS; Tapscott SJ; Storb R
    Mol Ther; 2007 Jun; 15(6):1160-6. PubMed ID: 17426713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Immunomodulatory Treatments on Anti-Dystrophin Immune Response After AAV Gene Therapy in Dystrophin Deficient mdx Mice.
    Li N; Parkes JE; Spathis R; Morales M; Mcdonald J; Kendra RM; Ott EM; Brown KJ; Lawlor MW; Nagaraju K
    J Neuromuscul Dis; 2021; 8(s2):S325-S340. PubMed ID: 34569971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy.
    Athanasopoulos T; Foster H; Foster K; Dickson G
    Methods Mol Biol; 2011; 709():21-37. PubMed ID: 21194019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy of Duchenne dystrophy.
    Ho PP; Lahey LJ; Mourkioti F; Kraft PE; Filareto A; Brandt M; Magnusson KEG; Finn EE; Chamberlain JS; Robinson WH; Blau HM; Steinman L
    Proc Natl Acad Sci U S A; 2018 Sep; 115(39):E9182-E9191. PubMed ID: 30181272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice.
    Bostick B; Yue Y; Lai Y; Long C; Li D; Duan D
    Hum Gene Ther; 2008 Aug; 19(8):851-6. PubMed ID: 18666839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy.
    Le Guiner C; Servais L; Montus M; Larcher T; Fraysse B; Moullec S; Allais M; François V; Dutilleul M; Malerba A; Koo T; Thibaut JL; Matot B; Devaux M; Le Duff J; Deschamps JY; Barthelemy I; Blot S; Testault I; Wahbi K; Ederhy S; Martin S; Veron P; Georger C; Athanasopoulos T; Masurier C; Mingozzi F; Carlier P; Gjata B; Hogrel JY; Adjali O; Mavilio F; Voit T; Moullier P; Dickson G
    Nat Commun; 2017 Jul; 8():16105. PubMed ID: 28742067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice.
    Zhang Y; Long C; Li H; McAnally JR; Baskin KK; Shelton JM; Bassel-Duby R; Olson EN
    Sci Adv; 2017 Apr; 3(4):e1602814. PubMed ID: 28439558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. rAAV6-microdystrophin rescues aberrant Golgi complex organization in mdx skeletal muscles.
    Percival JM; Gregorevic P; Odom GL; Banks GB; Chamberlain JS; Froehner SC
    Traffic; 2007 Oct; 8(10):1424-39. PubMed ID: 17714427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
    Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
    Science; 2004 Dec; 306(5702):1796-9. PubMed ID: 15528407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dystrophin Gene-Editing Stability Is Dependent on Dystrophin Levels in Skeletal but Not Cardiac Muscles.
    Bengtsson NE; Tasfaout H; Hauschka SD; Chamberlain JS
    Mol Ther; 2021 Mar; 29(3):1070-1085. PubMed ID: 33160075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy.
    Duan D
    Mol Ther; 2018 Oct; 26(10):2337-2356. PubMed ID: 30093306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy.
    Bostick B; Shin JH; Yue Y; Wasala NB; Lai Y; Duan D
    J Mol Cell Cardiol; 2012 Aug; 53(2):217-22. PubMed ID: 22587991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.